Physician profile
Deborah E Zell
NPI 1063623148
$2,337.77
in general payments reported to CMS, 2019-2025
26 companies · $221 in 2025
The $221 reported for 2025 was less than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $442 · 2020: $341 · 2021: $307 · 2022: $245 · 2023: $523 · 2024: $259 · 2025: $221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,002.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,002.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $616.07 | 2019-2025 | Rinvoq, Skyrizi |
| Amgen INC. | $237.33 | 2020-2024 | Otezla, Enbrel |
| Regeneron Healthcare Solutions, INC. | $197.59 | 2020-2024 | Libtayo |
| Leo Pharma INC. | $185.87 | 2019-2021 | |
| Genentech USA, INC. | $179.52 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $158.91 | 2022-2024 | Blu-U, Odomzo, Ilumya |
| Janssen Biotech, INC. | $117.16 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Mimedx Group, INC. | $101.18 | 2024-2025 | |
| Genzyme Corporation | $95.13 | 2019-2021 | |
| Dermavant Sciences, INC. | $58.42 | 2023 | Vtama |
| Almirall LLC | $56.33 | 2022-2025 | Seysara |
| Lilly USA, LLC | $44.02 | 2023 | Taltz, Olumiant |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $38.80 | 2023-2025 | Jublia |
| Mayne Pharma Commercial LLC | $25.08 | 2019-2025 | |
| Organogenesis INC. | $24.85 | 2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Surgenex LLC | $23.32 | 2025 | Pellograft, Ardeograft, Surgraft |
| Novartis Pharmaceuticals Corporation | $21.72 | 2023 | |
| Reprise Biomedical, INC. | $20.40 | 2025 | Miro3d |
| Arcutis Biotherapeutics, INC. | $20.24 | 2023 | |
| Kyowa Kirin, INC. | $19.55 | 2021 | |
| Incyte Corporation | $18.61 | 2021 | |
| Dusa Pharmaceuticals, INC. | $17.95 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.87 | 2023 | Cyltezo |
| Fidia Pharma USA INC. | $15.86 | 2024 | |
| Helsinn Therapeutics (U.S.), INC. | $15.45 | 2022 | |
| Galderma Laboratories, L.P. | $12.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Zell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.